profit from every $100 of sales.
$0$100
High Tide
$2.47-1.20% today
-13.9% in 1 year
1-year low $2.051-year high $2.92
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What High Tide sold, what it kept, and what it did with the cash.
Sales went from CA$357 million in 2022 to CA$594 million in 2025, with -CA$50.7 million of profit last year.
SalesProfit
High Tide vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| High Tide | No profit yet | ||
 Atai Beckley N.V | No profit yet | ||
 Avalyn Pharma | No profit yet | ||
 Cullinan Therapeutics | No profit yet | ||
 Satellos Bioscience | No profit yet |
AI analysis
An AI analyst reads High Tide's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 357 | 488 | 522 | 594 | |
| 101 | 131 | 143 | 154 | |
| -20 | -3 | 15 | 15 | |
| -34 | -4 | 34 | -14 | |
| -72 | -39 | -4 | -51 | |
| -1.14 | -0.53 | -0.05 | -0.62 | |
| 28.3% | 26.9% | 27.3% | 25.8% | |
| -5.6% | -0.5% | 2.9% | 2.6% | |
| -20.1% | -8.1% | -0.8% | -8.5% |
Balance sheet
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 275 | 233 | 246 | 349 |
| Cash | 25 | 30 | 47 | 48 |
| Total debt | 70 | 73 | 75 | 149 |
| Total liabilities | 113 | 100 | 101 | 246 |
| 156 | 132 | 143 | 88 | |
| 63 | 74 | 81 | 82 | |
| -22.3% | -14.3% | 3.0% | -12.7% | |
| -45.9% | -29.9% | -3.0% | -57.9% |
Cash flow
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 4 | 21 | 36 | 24 | |
| 9 | 6 | 10 | 11 | |
| -5 | 15 | 26 | 13 | |
| Dividends paid | 0 | – | – | – |
| – | – | – | – | |
| 8 | 5 | 3 | 4 |
Valuation
- –
- 59.5×
- –
- 3.3×
- 0.5×
- 23.8×
- –
- 4.2%
- -16.2%
- 0.0%
Profitability
- 25.8%
- 2.6%
- -8.5%
- -1.3%
- 5.3%
- -18.3%
- -40.9%
- -13.5%
- 5.9%
- –
Growth
- +18.5%
- –
- −48.8%
- –
- +18.0%
Financial health
- –
- 1.27
- 32.5%
- 1.0×
- 1.43
- 0.72
- 1.82
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 47%of 963
Bottom 29%of 894
Top 29%of 908
Top 27%of 991
What analysts expect
- Average price target
- $2.70
- Range
- $2.70 – $2.70
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 17, 2026 | 0.01 | -0.00 | +508.2% |
| Jan 29, 2026 | 0.01 | 0.00 | +180.1% |
| Sep 15, 2025 | 0.01 | -0.00 | +301.6% |
| Jun 16, 2025 | -0.03 | -0.03 | −12.9% |
| Mar 17, 2025 | -0.02 | -0.02 | −9.0% |
| Jan 29, 2025 | -0.04 | -0.02 | −100.0% |
| Sep 16, 2024 | 0.01 | 0.00 | +139.8% |
| Jun 13, 2024 | -0.00 | -0.00 | −76.9% |
News
Warren Buffett’s Berkshire Just Hit a Record High as Nvidia Sank. A 67-Year-Old Who Bought 1,000 Shares in 2016 Can Sell $106,000 of It This Year and Pay 0% on the GainYahoo Finance · Nov 14, 2026Home heating oil price declines from October high but still up 59% YoYSeeking Alpha · Nov 14, 2026Coca-Cola prints a new all-time high as the 'boring cash machine' rolls onSeeking Alpha · Nov 13, 2026Nebius Plummeted 33% in 3 Months: High Target Price Predicting 220% Gains Holds Steady Ahead of Q3 Earnings as Firm Avoids Nvidia EntanglementYahoo Finance · Nov 13, 20261 Reason to Still Avoid Wendy's Stock, Even Though It's 10% Below Its 52-Week HighYahoo Finance · Nov 13, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
16No pass
Benjamin Graham
19No pass
Philip Fisher
27No pass
Peter Lynch
48No pass
Joel Greenblatt
1No pass
Charlie Munger
10No pass
Terry Smith
17No pass
Questions about High Tide
Is High Tide a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the High Tide AI analysis
What does High Tide do?
High Tide Inc. engages in the cannabis retail business in Canada, Europe, the United States, and internationally. The company designs, manufactures, and distributes smoking accessories and cannabis lifestyle products. It is in Medical - Pharmaceuticals.
Does High Tide pay a dividend?
No. High Tide does not pay a dividend at the moment.
Is High Tide stock halal?
No. High Tide does not pass our halal screen: its debt is 47% of its market value, at or above the 33% limit. How we check
How has High Tide stock done over the past year?
Down 13.9% over the past twelve months, to $2.47. It traded between $2.05 and $2.92 and is 15.4% below its high.
Who are High Tide's competitors?
The largest listed companies in the same industry are Atai Beckley N.V, Avalyn Pharma, Cullinan Therapeutics and Satellos Bioscience. The peers table on this page compares their profit, growth and price with High Tide's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.